Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

BURLINGAME, Calif., May 25, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 4:00-4:25 pm ET. The presentation will be available via live webcast and accessible for 30 days afterwards through the investor relations section of Corvus' website.

Corvus focuses on developing innovative therapies, with lead candidate mupadolimab in Phase 3 trials for COVID-19 and ongoing studies for T-cell lymphomas. For detailed information, visit www.corvuspharma.com.

BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET.

A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. Mupadolimab is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

FAQ

What is the date and time of Corvus Pharmaceuticals' presentation at the Jefferies Virtual Healthcare Conference?

Corvus Pharmaceuticals will present on June 3, 2021, from 4:00-4:25 pm ET.

How can I access the webcast of Corvus Pharmaceuticals' conference presentation?

The webcast will be available live and for 30 days afterward via the investor relations section of Corvus Pharmaceuticals' website.

What is the main focus of Corvus Pharmaceuticals' lead product mupadolimab?

Mupadolimab is a monoclonal antibody targeting CD73, currently in Phase 3 trials for COVID-19.

What other clinical programs is Corvus Pharmaceuticals involved in?

Corvus is also investigating CPI-818 for T-cell lymphomas and CIF-444, an A2A receptor inhibitor.

What is the stock symbol for Corvus Pharmaceuticals?

The stock symbol for Corvus Pharmaceuticals is CRVS.